title: Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.
abstract: Triple-negative breast cancer (TNBC), as defined by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression, is a challenging disease with the poorest prognosis of all breast cancer subtypes. Importantly, there are currently no known molecular targets for this subgroup of patients. Recent advances in genomics and gene expression profiling have shed new light on the molecule heterogeneity of TNBC. We present an overview of the scientific evidence suggesting that clinical outcome in TNBC is affected by tumor-infiltrating immune cells. We also describe tumor-associated antigens recently identified in TNBC. Finally, we review the current literature on promising immunotherapies for TNBC, including tumor vaccine approaches, immune-checkpoint inhibitors, antagonists of immunosuppressive molecules and adoptive cell therapies. It is our contention that selected patients with TNBC with lymphocytic tumor infiltrates at diagnosis may benefit from immune-based therapies and that these immunotherapies will be most beneficial in combination with cytotoxic drugs that potentiate adaptive anti-tumor immunity.
authors: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada H2L 4M1.
authors: John
authors: J
authors: Stagg
authors: Bertrand
authors: B
authors: Allard
keywords: T cell; basal like; breast cancer; immunotherapy
references: Cancer Immunol Immunother. 2011 Mar;60(3):425-31
references: 21240484
references: Nature. 2006 Jul 27;442(7101):461-5
references: 16688182
references: Ann Oncol. 2011 Jan;22(1):98-103
references: 20610479
references: J Clin Invest. 2011 Jun;121(6):2371-82
references: 21537079
references: Cancer Res. 2011 Mar 15;71(6):2077-86
references: 21282337
references: Clin Lung Cancer. 2009 Sep;10(5):371-4
references: 19808198
references: Breast Cancer Res. 2011;13(6):R126
references: 22151962
references: Clin Cancer Res. 2011 Jul 1;17(13):4550-7
references: 21498393
references: Cancer Res. 2008 Jul 1;68(13):5405-13
references: 18593943
references: J Clin Invest. 2011 Jul;121(7):2750-67
references: 21633166
references: J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86
references: 21083648
references: Nature. 2012 May 16;486(7403):400-4
references: 22722201
references: Int J Cancer. 2007 Jun 1;120(11):2411-7
references: 17294444
references: Oncogene. 2005 Jul 7;24(29):4660-71
references: 15897907
references: Cancer Res. 2011 May 15;71(10):3540-51
references: 21430066
references: N Engl J Med. 2011 Aug 25;365(8):725-33
references: 21830940
references: Clin Cancer Res. 2009 Feb 1;15(3):971-9
references: 19188168
references: N Engl J Med. 2012 Jun 28;366(26):2455-65
references: 22658128
references: Hum Pathol. 2007 Feb;38(2):197-204
references: 17234468
references: Clin Cancer Res. 2008 Aug 15;14(16):5158-65
references: 18698033
references: Cancer Res. 2011 Feb 1;71(3):801-11
references: 21266358
references: Pathology. 2009 Jan;41(1):40-7
references: 19089739
references: Cancer Res. 2006 May 1;66(9):4636-44
references: 16651414
references: Cancer Res. 2000 Aug 15;60(16):4499-506
references: 10969798
references: Cancer. 2011 May 15;117(10):2192-201
references: 21523733
references: J Clin Oncol. 2010 Jan 1;28(1):105-13
references: 19917869
references: Oncogene. 2010 Sep 30;29(39):5346-58
references: 20661219
references: Clin Cancer Res. 2005 Jun 1;11(11):4003-11
references: 15930334
references: Cancer. 2007 May 1;109(9):1721-8
references: 17387718
references: Nat Med. 2009 Oct;15(10):1170-8
references: 19767732
references: PLoS One. 2012;7(6):e38783
references: 22761704
references: Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
references: 20080644
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
references: 20160101
references: Histopathology. 2006 Jul;49(1):22-34
references: 16842243
references: Nat Med. 2008 May;14(5):518-27
references: 18438415
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Breast Cancer Res. 2010;12(5):R68
references: 20813035
references: J Clin Oncol. 2012 Jun 1;30(16):1996-2004
references: 22508827
references: Breast Cancer Res Treat. 2012 Jun;133(2):799-804
references: 22418702
references: Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13493-8
references: 19651608
references: Mol Ther. 2010 Apr;18(4):843-51
references: 20179677
references: Breast Cancer Res Treat. 2009 Jan;113(2):357-70
references: 18324472
references: Cell Stem Cell. 2010 Sep 3;7(3):403-17
references: 20804975
references: J Clin Oncol. 2000 Feb;18(3):574-83
references: 10653872
references: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references: 15328174
references: Mol Immunol. 2008 Mar;45(5):1470-6
references: 17920123
references: Cancer. 2011 Apr 15;117(8):1602-11
references: 21472708
references: Breast Cancer Res. 2011 Oct 06;13(5):R97
references: 21978456
references: Clin Cancer Res. 2012 May 1;18(9):2695-703
references: 22351685
references: Cancer Discov. 2011 Jun;1(1):54-67
references: 22039576
references: Blood. 2010 Mar 11;115(10):1941-8
references: 20068221
references: Immunol Rev. 2007 Dec;220:82-101
references: 17979841
references: Eur J Cancer. 2012 Jan;48(1):12-23
references: 21741824
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references: 17671126
references: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16613-8
references: 12464682
references: Cancer Res. 2011 Dec 1;71(23):7259-69
references: 22006997
references: Breast Cancer Res Treat. 2009 May;115(2):423-8
references: 18543098
references: J Clin Oncol. 2011 Feb 20;29(6):610-8
references: 21245428
references: Trends Immunol. 2009 Nov;30(11):531-7
references: 19699678
references: Nat Rev Cancer. 2012 Mar 15;12(4):298-306
references: 22419253
references: J Clin Invest. 2006 Jul;116(7):1935-45
references: 16778987
references: Nat Immunol. 2012 Sep;13(9):832-42
references: 22842346
references: Cancer Res. 2012 Feb 15;72(4):917-27
references: 22186141
references: J Clin Oncol. 2011 May 20;29(15):1949-55
references: 21483002
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Nature. 2012 Apr 04;486(7403):395-9
references: 22495314
references: Trends Immunol. 2012 Mar;33(3):144-52
references: 22169337
references: Genome Biol. 2007;8(8):R157
references: 17683518
references: Cancer Res. 2011 Apr 15;71(8):2892-900
references: 21292811
references: Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34
references: 19202079
references: Blood. 1999 Jun 15;93(12):4309-17
references: 10361129
references: Cancer Res. 2011 Jul 15;71(14):4809-20
references: 21646474
references: J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
references: 14519755
references: Ann Oncol. 2010 Oct;21(10):1974-1981
references: 20332136
references: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references: 18316557
references: Cancer Res. 2005 Feb 1;65(3):1089-96
references: 15705911
references: Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6
references: 22171012
references: J Cell Biochem. 2012 Jun;113(6):2122-5
references: 22298331
references: Blood. 2010 Aug 19;116(7):1035-44
references: 20439624
references: J Exp Med. 2010 Sep 27;207(10):2187-94
references: 20819927
references: J Exp Med. 2008 Apr 14;205(4):825-39
references: 18362171
references: Breast Cancer Res. 2012 Mar 15;14(2):R48
references: 22420471
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: Cancer Res. 2012 May 1;72(9):2190-6
references: 22396496
references: Nat Med. 2012 Sep;18(9):1394-400
references: 22863785
references: J Clin Oncol. 2010 Jun 1;28(16):2784-95
references: 20404251
references: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references: 18250347
references: PLoS One. 2011 Mar 18;6(3):e17876
references: 21437249